Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
2017:83:1;69-70
doi: 10.4103/0378-6323.195074
PMID: 27917843

Author's reply

Kenit P Ardeshna, Shaurya Rohatgi, Hemangi R Jerajani
 Department of Dermatology, Venereology and Leprosy, MGM Medical College and Hospital, Navi Mumbai, Maharashtra, India

Correspondence Address:
Shaurya Rohatgi
502/A, Sai Prasad Residency, Kharghar Sector 10, Navi Mumbai - 410 210, Maharashtra
India
How to cite this article:
Ardeshna KP, Rohatgi S, Jerajani HR. Author's reply. Indian J Dermatol Venereol Leprol 2017;83:69-70
Copyright: (C)2017 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

We thank the authors for showing interest in our paper and accepting our arguments justifying the use of isotretinoin in dermatophytosis. While there are concerns on the rationality of this combination, we want to highlight yet again that the use of this combination should only be reserved for recalcitrant cases.[1]

It is likely that the increased cell turnover brought about by isotretinoin may result in faster clearance of itraconazole from the skin, thereby also reducing the reservoir effect. However, the argument put forward by the authors is based on concentration of any drug in isolation is of limited value and should ideally be analyzed along with concomitant pharmacodynamic data.[2] For example, amphotericin B deoxycholate and itraconazole have low concentrations in the cerebrospinal fluid yet they are effective agents for the treatment of cryptococcal meningitis.[2] Tissue homogenates are frequently used to estimate tissue concentrations but they are a relatively crude and potentially misleading matrix when used for this purpose.[2] Mouton et al. have highlighted the potential pitfalls in using drug concentrations within whole-tissue homogenates for drawing conclusions related to the activity and efficacy of a drug, especially for extracellular pathogens.[3] Moreover, studies trying to correlate in vitro dermatophyte minimal inhibitory concentrations with clinical outcomes have often failed to produce definitive results.[4] Despite our counterargument, we agree that further in-depth studies are required to evaluate the effect of isotretinoin on pharmacokinetics and pharmacodynamics of itraconazole.

Since isotretinoin decreases sebum production and sebum being a major route of delivery of itraconazole to the stratum corneum, it can possibly reduce the bioavailability of the drug to infected sites. Our first argument holds valid for this query as well. We do not know much about the impact of isotretinoin on the pharmacokinetics of itraconazole although it is plausible theoretically.

The final query was regarding inadequate duration of therapy resulting in poor response and possible relapse. We agree that continuing the same oral antifungal for longer period might have given better result. However, according to literature [5],[6],[7],[8] and dermatology textbooks,[9],[10], the recommended dose and duration of treatment for tinea cruris/corporis with oral itraconazole is 100 mg/day for 2 weeks or 200 mg/day for 1 week. In fact, this duration is also advocated in the package insert of itraconazole (Sporanox ®).[11] We used the same regimen for our patient; nevertheless considering the present scenario of relapsing dermatophytosis in our country, longer treatment schedule may be required.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References
1.
Ardeshna KP, Rohatgi S, Jerajani HR. Successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole. Indian J Dermatol Venereol Leprol 2016;82:579-82.
[Google Scholar]
2.
Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev 2014;27:68-88.
[Google Scholar]
3.
Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. Tissue concentrations: Do we ever learn? J Antimicrob Chemother 2008;61:235-7.
[Google Scholar]
4.
Martinez-Rossi NM, Peres NT, Rossi A. Antifungal resistance mechanisms in dermatophytes. Mycopathologia 2008;166:369-83.
[Google Scholar]
5.
Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-44.
[Google Scholar]
6.
De Doncker P, Cauwenbergh G. Management of fungal skin infections with 15 days itraconazole treatment: A worldwide review. Br J Clin Pract Suppl 1990;71:118-22.
[Google Scholar]
7.
Degreef H, Mariën K, De Veylder H, Duprez K, Borghys A, Verhoeve L. Itraconazole in the treatment of dermatophytoses: A comparison of two daily dosages. Rev Infect Dis 1987;9 Suppl 1:S104-8.
[Google Scholar]
8.
Korting HC, Schöllmann C. The significance of itraconazole for treatment of fungal infections of skin, nails and mucous membranes. J Dtsch Dermatol Ges 2009;7:11-9.
[Google Scholar]
9.
Elewski BE, Hughey LC, Sobera JO, Hay R. Fungal diseases. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. Philadelphia: Elsevier Saunders; 2012. p. 1251-84.
[Google Scholar]
10.
Hay RJ, Ashbee HR. Fungal infections. In: Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook's Textbook of Dermatology. 9th ed. Oxford: John Wiley & Sons, Ltd.; 2016. p. 32.1-96.
[Google Scholar]
11.
Sporanox ® (Itraconazole) Capsules [Package insert on the Internet]. Titusville, NJ, USA: Janssen Pharmaceuticals, Inc.; 2001. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020083s040s041s044lbl.pdf. [Last revised on 2014 Jun; Last accessed on 2016 Oct 11].
[Google Scholar]

Fulltext Views
39

PDF downloads
43
Show Sections